[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625810":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":17,"centralContacts":18,"locations":28,"responsibleParty":66,"collaborators":17,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":17,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":59,"whyStopped":17,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients with protected and unprotected familial hypercholesterolemia","Coronary computed tomography angiography with injection of iodinated contrast material",[12],"Other: Coronary computed tomography angiography",[14],{"type":6,"name":15,"description":10,"armGroupLabels":16,"otherNames":17},"Coronary computed tomography angiography",[9],null,[19,24],{"name":20,"role":21,"phone":22,"phoneExt":17,"email":23},"Antonio GALLO, MD, PhD","CONTACT","33(0)1 42 17 57 74","antonio.gallo@aphp.fr",{"name":25,"role":21,"phone":26,"phoneExt":17,"email":27},"Franck BOCCARA, MD, PhD","33(0)1 49 28 24 49","franck.boccara@aphp.fr",[29,47,57],{"facility":30,"status":31,"city":32,"state":17,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Plateau d'investigation clinique (PIC) IHU-ICAN","NOT_YET_RECRUITING","Paris","75013","France","FR",{"type":37,"coordinates":38},"Point",[39,40],2.3488,48.85341,{"lat":40,"lon":39},[43],{"name":44,"role":21,"phone":45,"phoneExt":17,"email":46},"Silvia Angela BARRETTA, PhD","01 84 827 7 63","s.barretta@ihuican.org",{"facility":48,"status":31,"city":32,"state":49,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":50,"geoPoint":52,"contacts":53},"APHP- Hospital Saint-Antoine","Île-de-France Region",{"type":37,"coordinates":51},[39,40],{"lat":40,"lon":39},[54,55],{"name":25,"role":21,"phone":26,"phoneExt":17,"email":27},{"name":25,"role":56,"phone":17,"phoneExt":17,"email":17},"PRINCIPAL_INVESTIGATOR",{"facility":58,"status":59,"city":32,"state":49,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"APHP-Sorbonne, Pitié Salpêtrière Hospital","RECRUITING",{"type":37,"coordinates":61},[39,40],{"lat":40,"lon":39},[64,65],{"name":20,"role":21,"phone":22,"phoneExt":17,"email":23},{"name":20,"role":56,"phone":17,"phoneExt":17,"email":17},{"type":67,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100625810","detection-and-follow-up-of-coronary-lesions-in-hefh-destiny-fh-study-100625810",false,"NCT07427472","\"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)\"","Detection and Longitudinal Follow-up of Non-calcified and Calcified Coronary Lesions in Heterozygous Familial Hypercholesterolemia (DESTINY-FH)","DESTINY-FH","Inclusion Criteria:\n\n1. Patients with heterozygous familial hypercholesterolemia\n2. Aged 30 to 60 years.\n3. Patients who underwent a CAC score and a coronary CT angiogram at least 5 years ago, exclusively at the same imaging center (ICT de la Pitié Salpetrière).\n4. Patient asymptomatic for exertional chest pain at the time of CCTA\n5. Clinical examination performed\n6. Beneficiary of a social protection scheme or entitled person (excluding AME)\n7. Patient informed and consent form signed\n\nExclusion Criteria:\n\n1. Patient under guardianship, or unable to give consent\n2. Pregnancy, breast-feeding\n3. Technical contraindication: weight \\> 250 kg\n4. Simultaneous participation in other interventional research involving the human body, or period of exclusion following previous research involving the human body still in progress.\n5. Adults subject to a legal protection order\n6. Contraindication to esmolol and\u002For atenolol\n7. Only for patients who need to undergo a CT angiogram and a thoraco-abdominal-pelvic CT scan:\n\n   * Renal insufficiency (LC\\\u003C60)\n   * Unbalanced diabetes when acquiring a previous coronary angioscanner\n   * Personal history of cardiovascular disease and myocardial infarction at the time of CCTA\n   * Contraindication to iodinated contrast media\n   * Patient having already had an adverse event (AE) during the acquisition of a prior coronary angioscanner","ALL","30 Years","60 Years",{"count":80,"type":81},300,"ESTIMATED","INTERVENTIONAL",[84],"NA","This multicenter, non-randomized interventional study aims to assess coronary artery disease progression over 5 years in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), using coronary computed tomography angiography (CCTA).\n\nThe primary endpoint is the visual evaluation of coronary stenosis using CAD-RADS v2.0, identifying changes between baseline (2018-2022) and study inclusion. The study will enroll 300 patients (100 protected, 200 non-protected) from La Pitié-Salpêtrière hospital and Saint Antoine Hospital (Paris). Participation lasts up to one week. Total study duration is 2 years, with extended follow-up through routine care data over 10 years.",[87],"Heterozygous Familial Hypercholesterolemia (HeFH)",[89,90,91,92,93],"Coronary Artery Disease","Atherosclerosis","Coronary Plaque Vulnerability","Cardiovascular Risk","Cardiovascular Events","2026-06-22",{"date":96,"type":97},"2026-06-24","ACTUAL",{"date":99,"type":97},"2026-06-19",{"date":101,"type":81},"2036-06-19",{"name":5,"class":6},3]